Theriva Biologics, Inc. (TOVX)
(Delayed Data from AMEX)
$0.37 USD
0.00 (-0.88%)
Updated May 17, 2024 03:56 PM ET
After-Market: $0.39 +0.02 (5.21%) 6:10 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Theriva Biologics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 22 | 14 | 10 | 16 |
Income After Depreciation & Amortization | -21 | -22 | -14 | -10 | -16 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -20 | -21 | -14 | -10 | -15 |
Income Taxes | -2 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -20 | -14 | -10 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -18 | -20 | -14 | -10 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -21 | -14 | -10 | -15 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -21 | -22 | -14 | -10 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.11 | 15.33 | 12.19 | 1.90 | 1.64 |
Diluted EPS Before Non-Recurring Items | -1.14 | -1.31 | -1.90 | -6.60 | -9.80 |
Diluted Net EPS (GAAP) | -1.14 | -1.31 | -1.90 | -6.60 | -9.80 |
Fiscal Year end for Theriva Biologics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.39 | 6.22 | 4.22 | 5.82 | 5.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.39 | -6.22 | -4.22 | -5.82 | -5.18 |
Non-Operating Income | 0.23 | 0.31 | 0.39 | 0.38 | 0.37 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.17 | -5.91 | -3.83 | -5.44 | -4.81 |
Income Taxes | 0.00 | -0.42 | -0.53 | -0.36 | -0.33 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.17 | -5.48 | -3.30 | -5.08 | -4.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.17 | -5.48 | -3.30 | -5.08 | -4.48 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 17.15 | 16.92 | 17.04 | 15.17 | 15.12 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.32 | -0.19 | -0.34 | -0.30 |
Diluted Net EPS (GAAP) | -0.30 | -0.31 | -0.19 | -0.34 | -0.30 |